Page 1 of 4

Matter No.: 00231-105001 Page 1 of Applicant(s): Richard Boismenu et al. USE OF SECRETIN AND SECRETIN ANALOGS TO TREAT AFFECTIVE DISORDERS




FIG. 1

Matter No.: 00231-105001 Page 2 of 4
Applicant(s): Richard Boismenu et al.
USE OF SECRETIN AND SECRETIN ANALOGS TO TREAT
AFFECTIVE DISORDERS




FIG. 2

Page 3 of 4

Matter No.: 00231-105001 Page 3 of Applicant(s): Richard Boismenu et al.
USE OF SECRETIN AND SECRETIN ANALOGS TO TREAT AFFECTIVE DISORDERS

Secretin (i.v.)	Day 1	Day 4	Day 9		
Control	15.85	7.86	7.80		
0.4 μg/kg	13.01	6.21*	6.26*		
4.0 μg/kg	13.12	6.40*	6.19**		
40.0 μg/kg	14.02	6.18*	7.86		

*P<0.05, ** P<0.01

FIG. 3

FIG. 4

EVALUATION SCHEDULE

	Screen	Day								
		1	3	4	10	17	24	31	32	59
RG1068 dose		_		9						
Recruit/SCID/	X									
psych eval etc.										_
Placebo injection		X					- "			
Injection training		X	X						_	
PK			X	X*				X	X*	
Chem/hem	X		X			X		X		X
Antibodies			X					X		X
Physical exam	X		X			X		X		X
YBOCS	X	X	X		X	X	X	X		X
CGI-S	X	X								X
CGI-C	,		X		X	X	X	X		X
HAM-A			X			X		X		X
Sickness Impact			X		X	X	X	X		X
Scale										
MADRS	X		X			X		X		X
Con Meds	X	X	X		X	X	X	X		X
AEs		X	X		X	X	X	X		X

^{*}Single blood sample 24 hours after last injection.